May is #LupusAwarenessMonth, a time to increase understanding and awareness of #lupus, a chronic autoimmune disease that can affect many parts of the body and impact daily life in complex and unpredictable ways. Learn more from Lupus Foundation of America, Inc.: https://lnkd.in/eq-MVfV
About us
Since its inception over a decade ago, CRISPR Therapeutics has evolved from a research-stage company advancing gene editing programs into a leader that celebrated the historic approval of the first-ever CRISPR-based therapy. The Company has a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases. In 2018, CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic to investigate the treatment of sickle cell disease and transfusion-dependent beta thalassemia. Beginning in late 2023, CASGEVY® (exagamglogene autotemcel [exa-cel]) was approved in several countries to treat eligible patients with either of these conditions. The Nobel Prize-winning CRISPR technology has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines. To accelerate and expand its efforts, CRISPR Therapeutics has formed strategic partnerships with leading companies including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California.
- Website
-
http://www.crisprtx.com
External link for CRISPR Therapeutics
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Boston, MA
- Type
- Public Company
- Founded
- 2013
- Specialties
- Gene Editing, Hematology, and Immuno-Oncology
Locations
-
Primary
Get directions
105 West First Street
Boston, MA 02127, US
-
Get directions
Baarerstrasse 14-16
Zug, CH CH-6300, CH
-
Get directions
90 Fetter Lane
London, England EC4A 1JP, GB
-
Get directions
455 Mission Bay Blvd S
San Francisco, California 94158, US
Employees at CRISPR Therapeutics
Updates
-
Today is #InternationalThalassemiaDay, dedicated to increasing awareness of #thalassemia, an inherited #BloodDisorder. Living with thalassemia can involve regular health monitoring and blood transfusions. We recognize people living with thalassemia, their families, and the global advocacy community. Learn more: https://lnkd.in/d9xCNcHT
-
-
Today, we announced our first quarter earnings results. Read more about our recent highlights and outlook in our business update: https://bit.ly/42KIqWv #CRSP
-
-
Congratulations to Stuart Orkin, MD, on receiving the 2026 Breakthrough Prize in Life Sciences. Stu’s foundational research identified BCL11A as the regulatory “off switch” for fetal hemoglobin, illuminating how to reactivate fetal hemoglobin production in adults. That work laid the scientific groundwork for the first approved CRISPR-based therapy, which we pioneered for people living with sickle cell disease and transfusion-dependent beta thalassemia. Congratulations also to Katherine High, MD, a member of our Board of Directors, and to Jean Bennett, Albert Maguire, and Swee Lay Thein. https://rb.gy/9al4cy #BreakthroughPrize
-
-
March 24 is Lipoprotein(a) Awareness Day. Elevated Lipoprotein(a), or Lp(a), is an inherited and often under-recognized risk factor for cardiovascular disease. This day recognizes individuals and families affected by elevated Lp(a) and the importance of awareness and education to #KnowLpa. Learn more from the Family Heart Foundation: https://lnkd.in/gKxwiuD8
-
-
Today, we announced our fourth quarter and full year earnings results. Read more about our recent highlights and outlook in our business update: bit.ly/3ZuYsCt
-
-
We’re entering the year with strong momentum across the pipeline. Today’s update outlines our strategic priorities and anticipated milestones, reflecting the breadth of our portfolio and continued execution of our long-term strategy. Learn more here: bit.ly/4pFadkn
-
-
We will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12th at 8:15 a.m. PT. A webcast and replay will be available on our website. #JPM2026 https://bit.ly/4qFoazD
-
-
Today, we shared a clinical update on zugo-cel (formerly known as CTX112™), reflecting continued progress across autoimmune disease and hematologic malignancies. The update includes advancement into the Phase 2 portion of the ongoing Phase 1/2 trial in oncology as we continue to evaluate zugo-cel across multiple disease settings. Learn more here: https://bit.ly/4p916YT
-
-
Today, we report financial results and business highlights for the third quarter 2025. Read more: https://bit.ly/3XkBk8t
-